Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 847.19
GLPGF's Cash to Debt is ranked higher than
76% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. GLPGF: 847.19 )
GLPGF' s 10-Year Cash to Debt Range
Min: 5.13   Max: No Debt
Current: 847.19

Equity to Asset 0.58
GLPGF's Equity to Asset is ranked higher than
65% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GLPGF: 0.58 )
GLPGF' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.77
Current: 0.58

0.5
0.77
F-Score: 5
Z-Score: 2.26
M-Score: -4.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -8.00
GLPGF's Operating margin (%) is ranked higher than
79% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. GLPGF: -8.00 )
GLPGF' s 10-Year Operating margin (%) Range
Min: -59.16   Max: 1.78
Current: -8

-59.16
1.78
Net-margin (%) -5.87
GLPGF's Net-margin (%) is ranked higher than
78% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. GLPGF: -5.87 )
GLPGF' s 10-Year Net-margin (%) Range
Min: -58.19   Max: 3.57
Current: -5.87

-58.19
3.57
ROE (%) -4.83
GLPGF's ROE (%) is ranked higher than
78% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. GLPGF: -4.83 )
GLPGF' s 10-Year ROE (%) Range
Min: -34.62   Max: 2.94
Current: -4.83

-34.62
2.94
ROA (%) -2.81
GLPGF's ROA (%) is ranked higher than
80% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. GLPGF: -2.81 )
GLPGF' s 10-Year ROA (%) Range
Min: -22.99   Max: 2.25
Current: -2.81

-22.99
2.25
ROC (Joel Greenblatt) (%) -56.44
GLPGF's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. GLPGF: -56.44 )
GLPGF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -168.69   Max: 6.57
Current: -56.44

-168.69
6.57
Revenue Growth (%) -1.80
GLPGF's Revenue Growth (%) is ranked higher than
74% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. GLPGF: -1.80 )
GLPGF' s 10-Year Revenue Growth (%) Range
Min: -1.8   Max: 39.9
Current: -1.8

-1.8
39.9
EPS Growth (%) 110.50
GLPGF's EPS Growth (%) is ranked higher than
100% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. GLPGF: 110.50 )
GLPGF' s 10-Year EPS Growth (%) Range
Min: -69.5   Max: 110.5
Current: 110.5

-69.5
110.5
» GLPGF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GLPGF



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.60
GLPGF's P/B is ranked higher than
86% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. GLPGF: 2.60 )
GLPGF' s 10-Year P/B Range
Min: 0.61   Max: 4.25
Current: 2.6

0.61
4.25
P/S 3.10
GLPGF's P/S is ranked higher than
91% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. GLPGF: 3.10 )
GLPGF' s 10-Year P/S Range
Min: 0.91   Max: 8.21
Current: 3.1

0.91
8.21
EV-to-EBIT -25.85
GLPGF's EV-to-EBIT is ranked higher than
78% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GLPGF: -25.85 )
GLPGF' s 10-Year EV-to-EBIT Range
Min: 40.5   Max: 128.7
Current: -25.85

40.5
128.7
Current Ratio 1.57
GLPGF's Current Ratio is ranked higher than
56% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. GLPGF: 1.57 )
GLPGF' s 10-Year Current Ratio Range
Min: 1.22   Max: 3.48
Current: 1.57

1.22
3.48
Quick Ratio 1.57
GLPGF's Quick Ratio is ranked higher than
59% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. GLPGF: 1.57 )
GLPGF' s 10-Year Quick Ratio Range
Min: 1.22   Max: 3.45
Current: 1.57

1.22
3.45

Valuation & Return

vs
industry
vs
history
Price/Net Cash 20.40
GLPGF's Price/Net Cash is ranked higher than
56% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. GLPGF: 20.40 )
GLPGF' s 10-Year Price/Net Cash Range
Min: 16.93   Max: 16.93
Current: 20.4

Price/Net Current Asset Value 20.20
GLPGF's Price/Net Current Asset Value is ranked higher than
55% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. GLPGF: 20.20 )
GLPGF' s 10-Year Price/Net Current Asset Value Range
Min: 11.43   Max: 99.38
Current: 20.2

11.43
99.38
Price/Tangible Book 3.60
GLPGF's Price/Tangible Book is ranked higher than
51% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. GLPGF: 3.60 )
GLPGF' s 10-Year Price/Tangible Book Range
Min: 1.83   Max: 3.53
Current: 3.6

1.83
3.53
Price/DCF (Projected) 3.30
GLPGF's Price/DCF (Projected) is ranked higher than
61% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GLPGF: 3.30 )
GLPGF' s 10-Year Price/DCF (Projected) Range
Min: 0   Max: 0
Current: 3.3

Price/Median PS Value 0.90
GLPGF's Price/Median PS Value is ranked higher than
51% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. GLPGF: 0.90 )
GLPGF' s 10-Year Price/Median PS Value Range
Min: 0.34   Max: 2.13
Current: 0.9

0.34
2.13
Forward Rate of Return (Yacktman) 0.38
GLPGF's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. GLPGF: 0.38 )
GLPGF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.6   Max: -4.2
Current: 0.38

-9.6
-4.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, LSE:0Q4U, BIIB » details
Traded in other countries:0JXZ.country, GLPG.Belgium, GLPG.Netherlands, GXE.Germany
Galapagos NV is a clinical stage biotech company focused on developing novel medicines. The company operates in two business divisions, R&D and Services. It also offers contract research services in the areas of in vitro, biology, analytics, among others. R&D operations specialize in the discovery and development of small molecules. Service operations offer target-to-drug discovery products and services to pharmaceutical and biotech companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
» More Articles for OTCPK:GLPGF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical... Jul 23 2014
BUZZ-Galapagos at 6-mnth low on drug trial update Jun 17 2014
Galapagos to hold Annual R&D Update on 17 June 2014 in New York May 12 2014
Invitation to the Extraordinary General Shareholders' Meeting to be held on 19 May 2014 Apr 30 2014
Galapagos announces management change Apr 28 2014
Baker Brothers notify of 4.99% shareholding in Galapagos Apr 24 2014
Galapagos, GSK successfully conclude phase 2a study of skin disease drug Apr 17 2014
GSK2586184 met primary endpoint in Phase 2a psoriasis study Apr 17 2014
Galapagos raises €2.4 million through warrant exercises Apr 10 2014
Charles River Laboratories and Galapagos complete transaction Apr 01 2014
Invitation to the Annual and Extraordinary General Shareholders' Meetings to be held on 29 April... Mar 28 2014
Euronext Amsterdam to become Market of Reference for Galapagos Mar 21 2014
Galapagos to present favorable pre-clinical data on GLPG1790, a selective ephrin receptor kinase... Mar 18 2014
Charles River Laboratories to Acquire the CRO Services Division of Galapagos NV Mar 13 2014
Charles River Laboratories to acquire Galapagos' Argenta and BioFocus service operations for up to... Mar 13 2014
Galapagos completes patient recruitment in Proof of Concept study with GLPG0974 in ulcerative... Mar 10 2014
Galapagos to present GLPG0634 and GLPG0974 at International Conference on IBD Mar 10 2014
Galapagos provides status update for GSK2586184 in GSK's psoriasis, lupus, and ulcerative colitis... Mar 10 2014
Galapagos receives €2 million from osteoarthritis alliance with Servier Mar 10 2014
Galapagos reports 2013 financial results Mar 10 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide